You know, I think we're in a catch 22 with this stock. As long as they can't meet demand for a daily lifetime dose medicine that is currently under clinical trials they have to be careful. They want positive feedback from those taking the medicine without a lapse in the doseage, which would cause negitive feedback. They can't afford even one disguntled patient. Keeping that in mind, their hands are tied as far as advertizing or hyping until they can meet demand at least locally. In the pharmaceutical world it's called "quiet time". They are letting out just enough positive info to keep the PPS from going subpenny. Now, when they get the loans they will still want to be careful until the plant is cranking out unlimited supply to start to cater to the masses. Then they have to complete the trials SUCCESSFULLY in Africa which should go hand in hand with mass availability. If you think about it XKEM has to walk a very bouncy tightrope till then. After they get a renewed license from successfully completing the trials they can lite all their candles on that rocket that will send this thing to the moon and beyond. All comments are welcome. Remember, I'm long on this thing...but I want a healthy bottom like everyone else. I just see subdued PRs and very little advertising and vague answers to questions by phone till they are solidly in control of all varibles. I think they love their shareholders, they just can't blow what they've accomplished up till now.